Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023 "Late Breaking" abstract scheduled for oral presentation on November 13

to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023

Breaking" abstract scheduled for oral presentation on November 13

LAKE CITY, November 01, 2023 -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System

(CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American

Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2023, to take place in Boston MA, November 10

is currently evaluating LPCN 1148 comprising testosterone laurate ("TL") for the management of decompensated cirrhosis. The

Company believes LPCN 1148 targets unmet needs for patients with advanced cirrhosis including improvement in the quality of life of patients

while on the liver transplant waiting list, prevention or reduction in the occurrence of new decompensation events such as hepatic encephalopathy

("HE"), and improvement in post liver transplant outcomes including survival and costs.

is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery

to develop differentiated products for CNS disorders. Lipocine has drug candidates in development as well as drug candidates for which

we are exploring partnering. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable

benefit to risk profile which target large addressable markets with significant unmet medical needs.

clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101

for the potential treatment of epilepsy and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for

the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate

for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated

cirrhosis, LPCN 1144, our candidate for treatment of non-cirrhotic NASH, and LPCN 1111, a once-a-day therapy candidate for testosterone

replacement therapy (TRT). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is

approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males.

For more information, please visit www.lipocine.com.

release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, the application

of our proprietary platform in developing new treatments for CNS disorders, our product candidates and related clinical trials, our development

of and filing of a NDA with the FDA for LPCN 1148,and the potential uses and benefits of our product candidates. Investors are cautioned

that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be

successful in developing product candidates to treat CNS disorders, we may not have sufficient capital to complete the development processes

for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets,

the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and

regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval

process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results

and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's

products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports

on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update

or revise publicly any forward-looking statements contained in this release, except as required by law.

further information: